<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03938272</url>
  </required_header>
  <id_info>
    <org_study_id>OC5-OL-02</org_study_id>
    <nct_id>NCT03938272</nct_id>
  </id_info>
  <brief_title>An Extension Study to Evaluate the Long-term Efficacy and Safety of Oxabact in Patients With Primary Hyperoxaluria</brief_title>
  <acronym>ePHex-OLE</acronym>
  <official_title>An Open-label Single-arm Treatment Extension Study to Evaluate the Long-term Efficacy and Safety of Oxabact for Patients With Primary Hyperoxaluria Who Completed Study OC5-DB-02</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OxThera</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>OxThera</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      OC5-OL-02 (ePHex-OLE) is a 2 year, open-label, extension study to evaluate the long-term
      efficacy and safety of Oxabact OC5 for patients with primary hyperoxaluria who completed
      study the parent double-blind, placebo-controlled study OC5-DB-02 (ePHex).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 3, 2019</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open-label study in which all patients will receive Oxabact OC5</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in kidney function (eGFR) after 12 and 24 months of open-label Oxabact treatment</measure>
    <time_frame>104 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Hyperoxaluria, Primary</condition>
  <arm_group>
    <arm_group_label>Oxabact OC5 capsules</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oxabact OC5 - Oxalobacter formigenes Strain HC-1</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Oxabact OC5 - Oxalobacter formigenes Strain HC-1</intervention_name>
    <description>Live, commensal bacteria</description>
    <arm_group_label>Oxabact OC5 capsules</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed informed consent (as applicable for the age of the subject).

          2. Participation in and completion of study OC5-DB-02.

          3. Subjects who had received vitamin B6 during OC5-DB-02 study should maintain a stable
             dose. Subjects not receiving vitamin B6 during OC5-DB-02 must be willing to refrain
             from initiating pyridoxine during study participation.

        Exclusion Criteria:

          1. Inability to swallow size 4 capsules.

          2. Use of antibiotics to which O. formigenes is sensitive.

          3. Current treatment with a separate ascorbic acid preparation.

          4. Pregnant women (or women who are planning to become pregnant).

          5. Women of childbearing potential who are not using adequate contraceptive precautions.

          6. Presence of a medical condition that the Investigator considers likely to make the
             subject susceptible to adverse effect of study treatment or unable to follow study
             procedures or any condition that is likely to interfere with the study drug mechanism
             of action (such as abnormal GI function).

          7. Participation in any interventional study of another investigational product,
             biologic, device, or other agent or not willing to forego other forms of
             investigational treatment during this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bastian Dehmel, MD</last_name>
    <phone>004686600223</phone>
    <email>bastian.dehmel@oxthera.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Liège</name>
      <address>
        <city>Liège</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laure Collard, M.D.</last_name>
      <email>Laure.Collard@chu.ulg.ac.be</email>
    </contact>
    <investigator>
      <last_name>Laure Collard, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Bonn, Dept of Pediatric Nephrology</name>
      <address>
        <city>Bonn</city>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Indra Schulte, M.D.</last_name>
      <phone>+49 228 28733223</phone>
      <email>indra.schulte@ukbonn.de</email>
    </contact>
    <investigator>
      <last_name>Indra Schulte, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gema Ariceta, M.D.</last_name>
      <phone>+34 934893082</phone>
      <email>gariceta@vhebron.net</email>
    </contact>
    <investigator>
      <last_name>Gema Ariceta, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Free Hospital</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rayma Barros-Howe</last_name>
      <phone>+44 207 4726687</phone>
      <phone_ext>33262</phone_ext>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 3, 2019</study_first_submitted>
  <study_first_submitted_qc>May 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 6, 2019</study_first_posted>
  <last_update_submitted>June 18, 2020</last_update_submitted>
  <last_update_submitted_qc>June 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperoxaluria, Primary</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

